Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

111 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility B-cell Lymphoma NCT01788189

- 16/08/2019 - 1 Formulaire, 2 Groupes Item, 20 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT01788189

Eligibility B-Cell Lymphoma NCT02395601

- 02/02/2019 - 1 Formulaire, 2 Groupes Item, 26 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT02395601

Eligibility B-cell Lymphoma NCT02055924

- 01/02/2019 - 1 Formulaire, 2 Groupes Item, 37 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT02055924

Eligibility Renal Cell Carcinoma and B-Cell Non-Hodgkin's Lymphoma NCT00944905

- 27/08/2018 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00944905

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Infection Summary

- 12/08/2018 - 1 Formulaire, 4 Groupes Item, 19 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Communicable diseases, Infection; Laboratory culture, Anti-infectives
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Please record all presumed and confirmed invasive infections through the Week 13 visit. Record only one infection per form.

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Adverse Experiences

- 12/08/2018 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Adverse Experiences
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Any adverse experience is defined as a new or worsening pre-existing medical condition or complication occurring while on study, regardless of its perceived relationship to the drug. Please record all adverse experiences from the time of study entry through the Week 13 visit.

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Infusion Record - Therapy Dose - Day 7

- 06/08/2018 - 1 Formulaire, 5 Groupes Item, 32 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Infusion, Vital signs, Adverse Experiences, Infusion; Patient compliance
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Infusion Record - Dosimetric Dose - Day 0

- 06/08/2018 - 1 Formulaire, 4 Groupes Item, 29 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Infusion, Vital signs, Adverse Experiences
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Post Treatment Response - Follow-Up

- 25/07/2018 - 1 Formulaire, 10 Groupes Item, 39 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Diagnostic Imaging, Head/Neck, Diagnostic Imaging; Chest, Diagnostic Imaging, Abdomen, Diagnostic Imaging, Pelvis, Diagnostic Imaging, Other, Bone Marrow Biopsy, Measurable Lymphoma Disease, Non-Measurable Disease, Response to treatment
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - HAMA Results

- 25/07/2018 - 1 Formulaire, 2 Groupes Item, 6 Eléments de données, 1 Langue
Groupes Item: Administrative Data, HAMA Results
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Concomitant Medications & Transfusions

- 25/07/2018 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Concomitant Agent
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Please record all concomitant medications and transfusions from the time of study entry through the Week 13 visit. Include study-required medications (i.e. Lugol's solution or potassium iodide, paracetamol, and diphenhydramine).

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Post-Treatment Response - Week 7

- 25/07/2018 - 1 Formulaire, 10 Groupes Item, 39 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Diagnostic Imaging, Head/Neck, Diagnostic Imaging; Chest, Diagnostic Imaging, Abdomen, Diagnostic Imaging, Pelvis, Diagnostic Imaging, Other, Bone Marrow Biopsy, Measurable Lymphoma Disease, Non-Measurable Disease, Response to treatment
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial